Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Rating) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 410,700 shares, a growth of 50.5% from the April 30th total of 272,800 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is […]
Vivos Therapeutics (NASDAQ:VVOS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for […]
Vivos Therapeutics (NASDAQ:VVOS – Get Rating) had its price target cut by investment analysts at Craig Hallum to $5.00 in a research report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “na” rating on the stock. Craig Hallum’s price objective indicates a potential upside of 262.32% from the stock’s previous close. […]
Vivos Therapeutics (NASDAQ:VVOS – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered […]
Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Rating) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 512,900 shares, a decrease of 31.4% from the February 28th total of 747,700 shares. Based on an average trading volume of 2,110,000 shares, the short-interest ratio is […]